Drugs / 5AC
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT01305499 | Jul 2011 → Sep 2021 | acute myeloid leukemia | Hetty Carraway | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 5AC | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01305499 ↗ |
| Route | Intravenous | “5AC 50mg/m2 subcutaneously/intravenously for 10 days” NCT01305499 ↗ |
| Route | Subcutaneous | “5AC 50mg/m2 subcutaneously/intravenously for 10 days” NCT01305499 ↗ |